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Zhang and colleagues reported the G1463A variant
(c.1322G>A) that predicted an amino acid substitution
at a highly conserved position in tryptophan hydroxy-
lase-2 (TPH2) (p.Arg441His). Functional analysis of
441His showed an w80% loss in serotonin production
when expressed in PC12 cells. The authors’ genetic
data showed the presence of the 1463 A-allele in 9 of
87 elderly unipolar affective disorder (UP) patients (>60
years) and in 3 of 219 healthy control individuals.
Based on these finding, we genotyped the G1463A
variant in two large patient-control samples obtained in
northern-Sweden and Belgium. The northern-Swedish
sample was comprised of 135 UP patients (87 females,
48 males, mean age at inclusion was 56.6 years), 182 bi-
polar (BP) patients (96 females, 86 males, mean age at
inclusion was 56.3 years), and 364 healthy age-, gen-
der-, and ethnicity-matched control individuals. The
Belgian sample consisted of 182 UP patients (121 fe-
males, 61 males, mean age at inclusion was 46.6 years),
182 BP patients (99 females, 83 males, mean age at in-
clusion was 45.3 years) and 364 healthy age-, gender-,
and ethnicity-matched control individuals. Genotyping
was performed by pyrosequencing on a PSQTMHS96
pyrosequencer (http://www.pyrosequencing.com/) with
the use of 50-bio-GTTTATTCTGCAGGGACTTTGC-30 and
50-CGAAGGTCCTGCACCACA-30 as PCR primers and
50-GAAGTATACTGAGAAGG-30 as reverse sequencing
primer. We did not observe the A-allele in any of the pa-
tients nor in the control individuals. To confirm the va-
lidity of our pyrosequencing assay, we subsequently
sequenced genomic DNA of all patients and control indi-
viduals by using PCR-based direct sequencing with pri-
mers 50-AGCCTTTGACCCAAAGACAA-30 (forward) and
50-AGATCATGCTGGCAACAACA-30 (reverse). Sequence
trace files were analyzed for the occurrence of the
G1463A variant with novoSNP (Weckx et al., 2005) and
visual inspection. The sequencing data confirmed the
absence of the 1463A-allele in all subjects. This unex-
pected absence of the TPH2 1463A-allele in 681 patients
with affective disorders and 728 control individuals from
two independent patient-control cohorts obtained from
northern-Sweden and Belgium raises doubts about the
true nature of this polymorphism. Even if the A-allele
was rare in our Caucasian populations, it would have
a frequency of <1/2818 chromosomes, or <0.035%.
This contradicts the high prevalence of this polymor-
phism in 15/662 chromosomes (2.3%) in Caucasians
reported by Zhang et al. (2005). Because the authors
selected older patients (>60 years) for their study, we
cannot exclude that the A-allele is enriched due to an as-
sociated protective survival effect. However, because
the frequency of affective disorders is very similar world-
wide and no studies have reported increased survival
due to reduced serotonin levels, this assumption is un-
likely to explain their genetic data. Furthermore, 7 of the
9 depressed patients with the 1463A-allele failed to re-
spond to SSRI treatment, while 2 patients required high
concentration. Therefore, it seems more plausible that
the observed high frequency of the 1463A-allele reported
by Zhang et al. (2005) is the result of severe patient pop-
ulation stratification based on age of inclusion and/or
SSRI treatment failure. Anyway, even with the strong
functional data of which we do not doubt the quality, the
report of a functional relevant genetic THP2 polymor-
phism associated with affective disorders is at this stage
uncertainand needs tobe replicated independently. Even
more, recent guidelines for genetic association studies
in complex diseases are firm when it comes to sample
sizes and replication, even for functionally relevant var-
iants in important candidate genes, and therefore war-
rant genotyping the G1463A variant in large patient-
control populations (Smyth et al., 2005; Qu et al., 2005).
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We genotyped 1023 samples from human subjects with
a diagnosis of unipolar depression for the neuronal
tryptophan hydroxylase-2 (TPH2) mutation reported by
Zhang et al. (2005). With the use of a Taqman 50 nuclease
assay (ABI, Assay by Design) we genotyped the entire
Genetics of Response to Antidepressant Drugs (GRAD)
sample at the G1463A TPH2 mutation and did not
several research groups. This G1463A polymorphism
was identified in several individuals within a small cohort
of patients with unipolar major depression (n = 87). This
coding missense mutation (R441H) causes an w80%
loss of function in the neuronal-specific TPH2, which
could have significant physiological consequence on
brain serotonin synthesis (Zhang et al., 2004). We con-
cluded that such mutation might provide a potential
mechanism underlying dysfunction in serotonin neuro-
transmission but that further genetic studies would be
needed to investigate the inheritance and penetrance
of this polymorphism in unipolar major depression.
Originally, we identified the G1463A polymorphism in
an individual by direct sequencing. Subsequently, sev-
eral more individuals carrying this mutation were identi-
fied in a cohort of unipolar major depression by allele-
specific ARMS-PCR (Zhang et al., 2005). To further
validate the presence of the mutation in these individu-
als, amplification of a 720 bp PCR product (forward: 50-
ATGCCTTATCACCACCTTCC and reverse: 50-TTAGAT
CTGAAAAAGAAAAGGGC) was performed. PCR prod-
ucts were purified and genotyped by sequence analysis
on both strands. Furthermore, the G1463A polymor-
phism was subsequently confirmed in one of our sam-
ples by Zhou et al. (2005) and Glatt et al. (2005).
In the accompanying letters, Van Den Bogaert et al.
(2005), Glatt et al. (2005), and Zhou et al. (2005) report
that they failed to identify this mutation in several other
depression cohorts, pointing to the rarity of this mutation
compared to its apparent high frequency in our study.
The most plausible explanation for this difference is
that the unipolar major depression cohort we had access
to represents a unique and different cohort of depression
patients as compared to the other groups’ cohorts. The
subjects in our study (n = 87) were 60 years of age or
older, and they were recruited from either our inpatient
program or through our mood disorder program. Most
of the patients were severely ill, and many were refrac-
tory to treatment. Interestingly, 5 of the 9 subjects carry-
ing the G1463A polymorphism were treated with electro-
convulsive therapy (ECT), while only 16 subjects in this
cohort of 87 received ECT. Therefore, the G1463A poly-
morphism may be present in a subset of unipolar major
depression associated with severe symptoms that are
resistant to treatment. ECT is relatively rarely used, and
the fact that a high proportion of these subjects had ECT
raises the possibility that this mutation may reflect a very
small subset of very ill, refractory depressed patients.
Unipolar major depression is a complex heteroge-
neous mood disorder with markedly different clinical
profiles and responses to drug treatment (Lesch, 2004;
DSM IV), and may also represent disorders with different
endophenotypes (Hasler et al., 2004). Genetic and envi-
ronmental as well as biochemical influences are thought
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705identify any instances of the variant (A) allele. We vali-
dated our genotyping assay by using genomic DNA
from individuals representing all genotypes in the origi-
nal report (DNA generously provided by M. Caron).
These samples displayed the anticipated genotypes in
our assay, consistent with those reported by Zhang et al.
The GRAD sample consists of 1023 individuals with
a broad ethnic representation (57% European American,
14% Hispanic, 13% African American, 6% Asian, and
10% Other). All GRAD subjects were assessed in semi-
structured interviews and met DSM-IV criteria for major
depression. The diagnosis of major depression was
confirmed by using the diagnostic interview for genetic
studies (DIGS) depression module. According to the re-
port by Zhang et al. for the depressed subjects in their
association analysis, we would have expected a fre-
quency for the variant (1463A) allele of roughly 0.07, or
72 occurrences. The GRAD sample has high power to
identify variant alleles with frequencies >0.005.
Our failure to find the A allele of G1463A in the GRAD
sample suggests that this mutation is quite rare in human
populations, even when focusing on samples consisting
of subjects with major depression. As reported by Zhang
et al., 1463A has a marked effect on the activity of TPH2
and might therefore play a role in rare, familial forms of
depression, but its absence from the GRAD sample sug-
gests that it does not play a substantial role in the popu-
lation prevalence of major depressive disorder.
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The TPH2 G1463A polymorphism that we recently re-
ported (Zhang et al., 2005) has raised interest among
to underlie the manifestations of depression (Hasler
et al., 2004; Lesch, 2004; DSM IV). Numerous studies
have indicated that depression is a polygenic disorder
associated with polymorphism(s) in several genes, in-
cluding the serotonin transporter, serotonin receptors,
the vesicular monoamine transporter, and monoamine
oxidases, as well as TPH1 and TPH2. Two hypotheses
have been suggested to explain the genetic basis of
polygenic disorders: the common disease/common var-
iant (CD/CV) hypothesis, where disease susceptibility
